GSA Capital Partners’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.53M | Buy |
339,902
+152,083
| +81% | +$792K | 0.1% | 274 |
|
|
2025
Q4 | $1.16M | Buy |
+187,819
| New | +$1.36M | 0.1% | 285 |
|
|
2025
Q3 | – | Sell |
-11,215
| Closed | -$60K | – | 1938 |
|
|
2025
Q2 | $60K | Buy |
+11,215
| New | +$66.2K | ﹤0.01% | 1653 |
|
|
2025
Q1 | – | Sell |
-26,236
| Closed | -$360K | – | 1935 |
|
|
2024
Q4 | $360K | Buy |
26,236
+7,816
| +42% | +$144K | 0.03% | 1104 |
|
|
2024
Q3 | $505K | Buy |
+18,420
| New | +$499K | 0.04% | 899 |
|
|
2020
Q2 | – | Sell |
-18,997
| Closed | -$272K | – | 934 |
|
|
2020
Q1 | $272K | Buy |
18,997
+6,297
| +50% | +$133K | 0.07% | 545 |
|
|
2019
Q4 | $346K | Buy |
12,700
+3,200
| +34% | +$88K | 0.04% | 913 |
|
|
2019
Q3 | $272K | Buy |
+9,500
| New | +$277K | 0.04% | 988 |
|
|
2019
Q2 | – | Sell |
-62,224
| Closed | -$2.07M | – | 1637 |
|
|
2019
Q1 | $2.07M | Buy |
62,224
+10,999
| +21% | +$335K | 0.21% | 58 |
|
|
2018
Q4 | $1.49M | Buy |
51,225
+27,525
| +116% | +$990K | 0.17% | 104 |
|
|
2018
Q3 | $1.09M | Sell |
23,700
-37,100
| -61% | -$1.65M | 0.06% | 634 |
|
|
2018
Q2 | $2.27M | Sell |
60,800
-20,000
| -25% | -$676K | 0.11% | 213 |
|
|
2018
Q1 | $2.39M | Sell |
80,800
-18,258
| -18% | -$618K | 0.13% | 196 |
|
|
2017
Q4 | $3.4M | Buy |
99,058
+26,058
| +36% | +$879K | 0.21% | 59 |
|
|
2017
Q3 | $2.64M | Buy |
73,000
+600
| +0.8% | +$17.1K | 0.18% | 77 |
|
|
2017
Q2 | $1.87M | Sell |
72,400
-49,658
| -41% | -$1.05M | 0.12% | 183 |
|
|
2017
Q1 | $2.34M | Sell |
122,058
-28,679
| -19% | -$508K | 0.13% | 196 |
|
|
2016
Q4 | $2.51M | Sell |
150,737
-1,302
| -0.9% | -$23.6K | 0.15% | 136 |
|
|
2016
Q3 | $3.13M | Buy |
152,039
+6,976
| +5% | +$177K | 0.17% | 89 |
|
|
2016
Q2 | $4.44M | Buy |
145,063
+15,735
| +12% | +$547K | 0.25% | 26 |
|
|
2016
Q1 | $4.84M | Buy |
129,328
+3,396
| +3% | +$128K | 0.31% | 8 |
|
|
2015
Q4 | $5.43M | Buy |
125,932
+49,395
| +65% | +$2.09M | 0.27% | 25 |
|
|
2015
Q3 | $2.87M | Buy |
76,537
+28,400
| +59% | +$1.01M | 0.14% | 129 |
|
|
2015
Q2 | $1.64M | Sell |
48,137
-12,000
| -20% | -$408K | 0.06% | 523 |
|
|
2015
Q1 | $2.13M | Sell |
60,137
-13,011
| -18% | -$466K | 0.08% | 316 |
|
|
2014
Q4 | $2.49M | Buy |
73,148
+29,817
| +69% | +$1.06M | 0.17% | 90 |
|
|
2014
Q3 | $1.67M | Buy |
43,331
+32,846
| +313% | +$1.23M | 0.09% | 252 |
|
|
2014
Q2 | $408K | Sell |
10,485
-1,843
| -15% | -$68.6K | 0.02% | 1259 |
|
|
2014
Q1 | $421K | Sell |
12,328
-17,635
| -59% | -$546K | 0.03% | 904 |
|
|
2013
Q4 | $629K | Sell |
29,963
-59,193
| -66% | -$1.5M | 0.05% | 662 |
|
|
2013
Q3 | $2.1M | Buy |
89,156
+68,648
| +335% | +$1.95M | 0.17% | 110 |
|
|
2013
Q2 | $551K | Buy |
+20,508
| New | +$594K | 0.07% | 489 |
|
Other funds holding MYGN
O
GCM
VCM
VPM
GSA Capital Partners's MYGN Position: Q1 2026 in Review
GSA Capital Partners increased its Myriad Genetics (MYGN) stake by 81% in Q1 2026, buying an estimated $792K and bringing the position to 339,902 shares worth $1.53M. The position accounts for 0.1% of the portfolio, ranked #274.
GSA Capital Partners first reported a position in MYGN in Q2 2013 and has held it in 32 quarters since. The position peaked at $5.43M in Q4 2015. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.
- GSA Capital Partners held 339,902 shares of Myriad Genetics worth $1.53M as of Q1 2026.
- GSA Capital Partners bought 152,083 Myriad Genetics shares in Q1 2026, an estimated $792K.
- Myriad Genetics made up 0.1% of GSA Capital Partners's portfolio in Q1 2026, its #274 holding.
- GSA Capital Partners first reported a position in Myriad Genetics in Q2 2013 and has held it in 32 quarters since.
- GSA Capital Partners's Myriad Genetics position peaked at $5.43M in Q4 2015.
- 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.
Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.